Jules Bordet Institute registers Phase 2 scalp cooling trial for ADC-related hair loss
Gilead Sciences and Paxman join as collaborators on a study testing scalp cooling against alopecia from antibody-drug conjugates including trastuzumab-deruxtecan and sacituzumab-govitecan.
One trial update this week involving Gilead Sciences as a collaborator rather than sponsor.
- "SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates" (SCARLET-ICE, NCT07474558) is a Phase 2 study sponsored by the Jules Bordet Institute, with BelleTorus Corporation, Gilead Sciences, and Paxman listed as collaborators. The trial is recruiting, with an actual start date of 2026-10-23 and estimated primary completion of 2030-01-15.1 It will evaluate whether scalp cooling reduces chemotherapy-induced alopecia in patients with advanced or metastatic solid tumors receiving trastuzumab-deruxtecan, sacituzumab-govitecan, or datopotamab-deruxtecan, comparing an ADC-plus-cooling arm against an ADC-only control arm.1 The study plans to enroll 102 participants, with the experimental arm receiving scalp cooling alongside photographs taken via the Belle.AI app.1 The primary outcome is the percentage of participants with hair loss, defined as a Severity of Alopecia Tool (SALT) score greater than zero.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.